Tri Locum Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History
Bought
Maintained
Sold
Other funds holding MDGL
BBA
Tri Locum Partners's MDGL Position: Q3 2026 in Review
Tri Locum Partners reduced its Madrigal Pharmaceuticals (MDGL) stake by 51% in Q3 2026, selling an estimated $18.3M and leaving 33,668 shares worth $17M. The position accounts for 3.35% of the portfolio, ranked #13.
Tri Locum Partners first reported a position in MDGL in Q4 2022 and has held it in 16 quarters since. The position peaked at $54.1M in Q1 2026. 435 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.
- Tri Locum Partners held 33,668 shares of Madrigal Pharmaceuticals worth $17M as of Q3 2026.
- Tri Locum Partners sold 34,605 Madrigal Pharmaceuticals shares in Q3 2026, an estimated $18.3M.
- Madrigal Pharmaceuticals made up 3.35% of Tri Locum Partners's portfolio in Q3 2026, its #13 holding.
- Tri Locum Partners first reported a position in Madrigal Pharmaceuticals in Q4 2022 and has held it in 16 quarters since.
- Tri Locum Partners's Madrigal Pharmaceuticals position peaked at $54.1M in Q1 2026.
- 435 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.
Based on Tri Locum Partners's 13F filing for Q3 2026, filed 16 Nov 2026.